{"gene":"MTTP","run_date":"2026-04-29T11:37:56","timeline":{"discoveries":[{"year":1992,"finding":"MTP activity and its 88-kDa large subunit are absent in intestinal biopsy samples from abetalipoproteinemia patients, establishing that a defect in MTP is the molecular basis of abetalipoproteinemia and that MTP is required for lipoprotein assembly.","method":"MTP activity assay and immunodetection in intestinal biopsies from ABL patients vs. controls","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical assay in patient tissue, foundational discovery replicated across multiple independent groups","pmids":["1439810"],"is_preprint":false},{"year":1993,"finding":"cDNA cloning of the large subunit of MTP revealed homozygous frameshift and nonsense mutations in two abetalipoproteinemic subjects, proving that defects in the MTP large-subunit gene are the proximal cause of ABL. The predicted amino acid sequence shows extensive homology to vitellogenin, which contains a large lipid-storage cavity.","method":"cDNA cloning, sequencing, and comparative genomic analysis; cell expression in COS-1 cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — cloning plus patient mutation identification, replicated by independent groups same year","pmids":["8361539"],"is_preprint":false},{"year":1993,"finding":"The human MTP gene was cloned and localized to chromosome 4q22-24. The C-terminal portion of MTP is necessary for triglyceride-transfer activity: deletion of 20 amino acids from the carboxyl terminus or a missense mutation of Cys878→Ser both abolished activity. Homozygous splice-disrupting mutations were identified in ABL patients.","method":"cDNA cloning, site-directed mutagenesis, expression in COS-1 cells with activity assay, patient mutation identification","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis plus in vitro activity assay defining required structural domain","pmids":["8111381"],"is_preprint":false},{"year":1994,"finding":"MTP gene promoter analysis showed cell-type-specific expression restricted to liver and intestinal cells, mediated by HNF-1 and HNF-4 binding elements in the -123 to -85 bp region. The promoter contains a modified sterol response element and a negative insulin response element; cholesterol positively and insulin negatively regulate MTP promoter activity.","method":"Promoter cloning, deletion analysis, transient transfection/luciferase reporter assay in liver, intestinal, and epithelial cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — functional promoter dissection with multiple deletion constructs and cell-type comparisons","pmids":["7961826"],"is_preprint":false},{"year":1995,"finding":"All eight individuals in an ABL cohort carry mutations in the MTP gene on both alleles, each predicted to encode a truncated MTP protein, confirming MTP gene defects as the predominant cause of hereditary ABL and that an intact carboxyl terminus is required for triglyceride-transfer activity.","method":"MTP gene characterization, mutation screening across patient cohort, expression of engineered MTP forms in COS-1 cells","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis and expression assay across a patient cohort, confirming prior mechanistic findings","pmids":["8533758"],"is_preprint":false},{"year":1996,"finding":"The MTP inhibitor BMS-200150 directly binds bovine MTP (Kd ~1.3 µM) and inhibits its triglyceride transfer activity (IC50 ~0.6 µM). Addition to HepG2 cells inhibits apoB secretion in a concentration-dependent manner, establishing that MTP-mediated neutral lipid transfer is mechanistically required for assembly of apoB-containing lipoproteins.","method":"In vitro MTP lipid transfer assay, binding assay, HepG2 cell apoB secretion assay with pharmacological inhibitor","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstituted transfer assay plus binding assay plus cellular functional assay","pmids":["8876250"],"is_preprint":false},{"year":1997,"finding":"MTP is a heterodimer composed of the unique large (~88 kDa) subunit and protein disulfide isomerase (PDI); this complex catalyzes transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces and is located in the lumen of the ER in liver and intestine.","method":"Biochemical purification, activity assays, subunit characterization","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution and purification, widely replicated","pmids":["9106493"],"is_preprint":false},{"year":1997,"finding":"MTP plays a key early role in lipoprotein assembly by transferring lipid to nascent apoB as it enters the ER lumen; MTP controls the number of apoB lipoprotein particles secreted but does not primarily determine the lipid composition of the particles.","method":"Heterologous expression systems and MTP inhibitor studies in hepatoma cell lines","journal":"Current opinion in lipidology","confidence":"Medium","confidence_rationale":"Tier 2 — convergent pharmacological and expression data from multiple systems, single review synthesis","pmids":["9211060"],"is_preprint":false},{"year":2000,"finding":"Six novel MTP gene mutations (two nonsense, two missense, one frameshift, one splice-donor) were identified in Canadian ABL subjects, demonstrating wide genotypic heterogeneity and showing that clinical severity correlates with age at diagnosis and vitamin treatment onset rather than mutation type or position.","method":"MTP gene sequencing in patient cohort, genotype-phenotype correlation","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic characterization of multiple novel loss-of-function alleles confirming MTP's essential role","pmids":["10679949"],"is_preprint":false},{"year":2003,"finding":"Insulin suppresses MTP gene transcription in HepG2 cells through the MAPKerk cascade (not PI3K), while MAPKp38 activity counterbalances this suppression, identifying the specific signal transduction pathways by which insulin regulates hepatic MTP expression and thereby VLDL production.","method":"Chemical inhibitors of signaling cascades, constitutively active and dominant-negative kinase constructs, MTP promoter-luciferase reporter assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal genetic and pharmacological approaches dissecting the signaling pathway","pmids":["12716735"],"is_preprint":false},{"year":2004,"finding":"The MTP gene promoter contains functional HNF-4α responsive elements, and HNF-4α regulates MTP expression directly and indirectly through HNF-1. Bile acid (CDCA) activates FXR, which induces small heterodimer partner (SHP), which suppresses HNF-4α activity, thereby reducing MTP mRNA, MTP protein, and apoB secretion.","method":"Chromatin immunoprecipitation (ChIP), siRNA knockdown, dominant-negative HNF-4α overexpression, MTP promoter-luciferase reporter assays in HepG2 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus siRNA plus reporter assay, multiple orthogonal methods","pmids":["15337761"],"is_preprint":false},{"year":2005,"finding":"MTP is expressed in retinal pigment epithelium (RPE) and retinal ganglion cells, and RPE cells (ARPE-19) synthesize and secrete neutral lipids (esterified cholesterol and triglyceride), implicating MTP-dependent lipoprotein assembly as a constitutive retinal function that may contribute to Bruch's membrane lipid deposition in age-related maculopathy.","method":"RT-PCR, immunodetection of MTP in retinal tissue and ARPE-19 cells; radiolabeled lipid secretion assay","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — direct detection of MTP expression plus functional lipid secretion assay in retinal cells","pmids":["15654125"],"is_preprint":false},{"year":2005,"finding":"MTP has two additional functional roles beyond VLDL/chylomicron assembly: (1) production of small apoB-containing lipoprotein particles in cardiac myocytes, and (2) lipidation of CD1d (an MHC class I-related molecule) that presents glycolipid antigens to natural killer T (NKT) cells.","method":"Review synthesizing experimental data including lipid transfer assays and CD1d lipidation studies","journal":"Current topics in medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — review synthesis of experimental findings from multiple labs","pmids":["15857311"],"is_preprint":false},{"year":2007,"finding":"MTP regulated by an alternative promoter is expressed as a novel splice variant (MTPv1) in non-apoB-secreting tissues including thymocytes and antigen-presenting cells. MTPv1 efficiently transfers phosphatidylethanolamine to CD1d in vitro. MTP inhibition in fetal thymic organ culture blocks NKT cell development and CD1d tetramer-positive cell generation, without affecting surface CD1d levels, establishing MTP's role in lipid loading of CD1d for NKT cell selection.","method":"PCR, Northern analysis, Edman degradation sequencing, in vitro phospholipid transfer to CD1d, fetal thymic organ culture with MTP antagonists, NKT cell quantification by tetramer staining","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro reconstitution of CD1d lipidation plus genetic/pharmacological loss-of-function in thymic organ culture with defined cellular phenotype","pmids":["17312007"],"is_preprint":false},{"year":2008,"finding":"IRE1β (an ER stress sensor isoform expressed in intestine) selectively degrades MTP mRNA post-transcriptionally, thereby suppressing intestinal MTP expression and chylomicron production. Ire1b-/- mice develop hyperlipidemia due to increased intestinal MTP expression and chylomicron secretion; IRE1α does not regulate MTP mRNA.","method":"Ire1b-/- mouse phenotyping, primary enterocyte isolation, siRNA knockdown of IRE1β in cell culture, measurement of MTP mRNA stability and chylomicron secretion","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus siRNA knockdown plus primary cell studies with defined molecular mechanism","pmids":["18460335"],"is_preprint":false},{"year":2008,"finding":"FoxO1 directly binds to and stimulates the MTP promoter, inducing MTP expression and VLDL production in a hepatic context. Constitutively active FoxO1 mice show enhanced MTP expression and hypertriglyceridemia; RNAi silencing of hepatic FoxO1 reduces MTP and VLDL production. Insulin suppresses MTP through inhibition of FoxO1.","method":"Promoter binding assays, FoxO1 transgenic mice, RNAi-mediated hepatic FoxO1 knockdown in adult mice, VLDL production and MTP activity measurements","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain- and loss-of-function with defined molecular and metabolic phenotypes","pmids":["18497885"],"is_preprint":false},{"year":2010,"finding":"CLOCK regulates diurnal MTP expression and plasma triglyceride cycling through the small heterodimer partner (SHP/NR0B2). CLOCK binds the SHP E-box to upregulate SHP, which then suppresses MTP by binding HNF-4α/LRH-1 at the MTP promoter. Clock(mt/mt) mice show sustained hypertriglyceridemia and high MTP expression; Shp-/- mice lose diurnal variation in both MTP and triglycerides; SHP expression corrects hypertriglyceridemia in Clock(mt/mt) mice.","method":"Clock mutant and Shp-/- mouse models, serum shock oscillation assays, siRNA knockdown, MTP promoter analysis, plasma triglyceride and MTP expression measurements","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — two genetic mouse models plus siRNA, defining a complete regulatory axis","pmids":["20674862"],"is_preprint":false},{"year":2012,"finding":"The IRE1α–XBP1s arm of the unfolded protein response regulates VLDL assembly via MTP. Hepatocyte-specific Ire1α deletion reduces lipid partitioning into the ER lumen and impairs TG-rich VLDL assembly without affecting TG synthesis or apoB synthesis/secretion. The defect is due to reduced MTP activity caused by decreased PDI expression; thus the IRE1α–XBP1s–PDI axis controls MTP activity.","method":"Hepatocyte-specific Ire1α knockout mice, VLDL lipid composition analysis, MTP activity assay, PDI expression measurement","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic knockout with mechanistic dissection identifying PDI as intermediate","pmids":["23040069"],"is_preprint":false},{"year":2012,"finding":"NR2F1 represses synergistic activation of the MTP promoter by HNF-4α/HNF-1α by binding to a DR1 element and recruiting nuclear receptor corepressor 1 (NCoR1), without affecting individual activities of HNF-4α or HNF-1α alone. This defines a mechanism for MTP repression in undifferentiated intestinal cells.","method":"MTP promoter-luciferase reporter assays, electrophoretic mobility shift assay (EMSA), co-transfection of HNF-4α, HNF-1α, NR2F1, and NCoR1","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter assays with defined transcription factor combinations","pmids":["22357705"],"is_preprint":false},{"year":2012,"finding":"Two novel MTTP mutations in an atypical ABL patient (missense p.Leu435His and intronic deletion c.619-5_619-2del) were characterized: the missense mutant showed negligible MTP activity in COS-1 cells; the intronic deletion caused incomplete splicing defect retaining 26% normal splicing, explaining the milder atypical phenotype through residual MTP activity.","method":"MTP activity assay in COS-1 cells (missense mutant expression), minigene splicing reporter assay in HeLa cells (intronic deletion)","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1–2 — functional activity assay plus splicing assay linking genotype to residual MTP function and atypical phenotype","pmids":["22236406"],"is_preprint":false},{"year":2013,"finding":"MicroRNA-30c (miR-30c) interacts with the 3' UTR of MTP mRNA and induces its degradation, reducing MTP activity and apoB secretion. miR-30c also independently reduces lipid synthesis. Hepatic overexpression of miR-30c in mice reduced hyperlipidemia and atherosclerosis; anti-miR-30c increased hyperlipidemia and atherosclerosis.","method":"3' UTR reporter assay, hepatic miR-30c overexpression and anti-miR knockdown in mice, MTP activity assay, VLDL/apoB secretion measurements, atherosclerosis quantification in Apoe-/- mice","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain- and loss-of-function with direct MTP activity measurement and 3' UTR validation","pmids":["23749231"],"is_preprint":false},{"year":2014,"finding":"Intestinal-specific MTP deletion increases intestinal triglyceride and cholesterol levels and reduces their transport with chylomicrons. Combined intestinal MTP and global ACAT2 deficiency reduces cholesterol secretion with both chylomicrons and HDLs, demonstrating that MTP is required for chylomicron assembly and that free cholesterol accumulated during ACAT2 deficiency is unavailable for HDL secretion when MTP is absent. ACAT2 deficiency increases hepatic MTP activity to compensate for hepatosteatosis.","method":"Intestine-specific MTP knockout mice, global ACAT2 knockout mice, double knockout mice; cholesterol absorption assay, lipoprotein fractionation, MTP activity assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic mouse models with precise metabolic phenotyping","pmids":["25030663"],"is_preprint":false},{"year":2020,"finding":"PRAP1 is a novel lipid-binding protein that colocalizes with MTTP in the ER and directly binds triglyceride. PRAP1 facilitates MTTP-mediated lipid transfer by forming a ternary complex with TG and MTTP; mutation E85V disrupts ternary complex formation and abolishes PRAP1's ability to facilitate MTTP-mediated apoB-containing lipoprotein assembly and secretion. PRAP1-deficient and E85V knock-in mice show reduced lipid absorption and resistance to diet-induced obesity and hepatosteatosis.","method":"Co-localization studies, direct TG-binding assay, MTTP-mediated lipid transfer assay, E85V mutagenesis, apoB lipoprotein secretion assay, PRAP1-KO and E85V knock-in mouse models on chow and HFD","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro binding and transfer assay plus mutagenesis plus in vivo mouse models, multiple orthogonal methods","pmids":["33168624"],"is_preprint":false},{"year":2022,"finding":"Adipocyte-derived exosomal MTTP is transferred to colorectal cancer (CRC) cells where it forms a complex with PRAP1; the MTTP/PRAP1 complex inhibits ZEB1 expression and upregulates GPX4 and xCT, decreasing polyunsaturated fatty acid ratio and lipid ROS levels, thereby suppressing ferroptosis and promoting chemoresistance to oxaliplatin. MTTP inhibition restored oxaliplatin sensitivity in CRC organoids and obese mouse tumor models.","method":"Exosome isolation and characterization, Co-IP of MTTP/PRAP1 complex, GPX4/xCT/ZEB1 expression analysis, lipid ROS measurement, CRC organoids, obese mouse tumor implantation model with MTP inhibitor treatment","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP defining complex plus multiple functional assays in organoids and in vivo models, single lab study","pmids":["35978266"],"is_preprint":false}],"current_model":"MTTP encodes a heterodimeric ER-luminal lipid transfer protein (large ~88-kDa subunit complexed with PDI) that is essential for lipoprotein assembly by transferring triglyceride, cholesteryl ester, and phospholipid to nascent apoB as it enters the ER lumen (controlling particle number rather than lipid composition); its transcription is regulated by HNF-4α/HNF-1α (positively), FoxO1 (insulin-repressible), CLOCK–SHP axis (circadian), bile acid–FXR–SHP (repressive), and miR-30c (post-transcriptional degradation), while IRE1β degrades MTP mRNA intestine-specifically and the IRE1α–XBP1s–PDI axis supports MTP activity in the liver; beyond canonical lipoprotein assembly, MTP lipidates CD1d to enable NKT cell development, is expressed in retina and cardiac myocytes, and an exosomal form suppresses ferroptosis in cancer cells via a MTTP–PRAP1 complex that regulates GPX4 and xCT."},"narrative":{"teleology":[{"year":1992,"claim":"Identification that MTP activity and its large subunit are absent in abetalipoproteinemia patients established MTP as essential for lipoprotein assembly and pinpointed the molecular defect underlying ABL.","evidence":"MTP activity assay and immunodetection in intestinal biopsies from ABL patients versus controls","pmids":["1439810"],"confidence":"High","gaps":["Precise molecular identity and sequence of the large subunit not yet known","Mechanism of lipid transfer not resolved"]},{"year":1993,"claim":"Cloning of the MTP large subunit cDNA and identification of loss-of-function mutations in ABL patients proved the gene is causative for ABL and revealed structural homology to vitellogenin, suggesting a lipid-binding cavity architecture; mutagenesis demonstrated the C-terminal domain is required for triglyceride transfer activity.","evidence":"cDNA cloning, patient mutation identification, site-directed mutagenesis, COS-1 cell expression and activity assay","pmids":["8361539","8111381"],"confidence":"High","gaps":["No crystal structure to define lipid-binding cavity directly","Heterodimer formation requirements not yet mapped"]},{"year":1994,"claim":"Dissection of the MTP promoter revealed cell-type-specific regulation by HNF-1 and HNF-4, a sterol response element, and a negative insulin response element, explaining tissue-restricted expression in liver and intestine.","evidence":"Promoter deletion analysis, luciferase reporter assays in liver, intestinal, and non-expressing cell lines","pmids":["7961826"],"confidence":"High","gaps":["In vivo relevance of each promoter element not tested","Post-transcriptional regulation not yet explored"]},{"year":1996,"claim":"Pharmacological inhibition of MTP with a specific small molecule (BMS-200150) demonstrated that neutral lipid transfer activity is mechanistically required for apoB-containing lipoprotein secretion, rather than just correlated with it.","evidence":"In vitro lipid transfer assay, direct binding measurement, apoB secretion assay in HepG2 cells with MTP inhibitor","pmids":["8876250"],"confidence":"High","gaps":["Structural basis of inhibitor binding unknown","In vivo pharmacokinetics not established"]},{"year":1997,"claim":"Biochemical characterization established MTP as an ER-luminal heterodimer of the unique 88 kDa subunit with PDI that transfers TG, CE, and PL, and showed MTP controls particle number rather than lipid composition.","evidence":"Biochemical purification and reconstituted lipid transfer assays; pharmacological and expression studies in hepatoma cells","pmids":["9106493","9211060"],"confidence":"High","gaps":["Mechanism by which PDI contributes to transfer activity not defined","Structural basis of lipid substrate selectivity unknown"]},{"year":2004,"claim":"The HNF-4α→HNF-1α transcriptional axis was shown to directly activate MTP, while the bile acid–FXR–SHP pathway suppresses MTP by inhibiting HNF-4α at the promoter, connecting bile acid signaling to VLDL output.","evidence":"ChIP, siRNA knockdown, dominant-negative constructs, MTP promoter-luciferase in HepG2 cells","pmids":["15337761"],"confidence":"High","gaps":["In vivo validation in FXR or SHP knockout liver not yet performed in this study","Contribution of SHP-independent FXR effects not ruled out"]},{"year":2007,"claim":"Discovery of an alternative-promoter-driven MTP isoform in thymocytes and APCs that transfers phospholipid to CD1d established a non-canonical function of MTP in NKT cell development, independent of apoB-lipoprotein assembly.","evidence":"Identification of MTPv1 splice variant, in vitro phospholipid transfer to CD1d, fetal thymic organ culture with MTP antagonists and NKT cell quantification","pmids":["17312007"],"confidence":"High","gaps":["Lipid species loaded onto CD1d by MTP in vivo not fully characterized","Whether MTPv1 also transfers neutral lipids in immune cells not tested"]},{"year":2008,"claim":"Two opposing post-transcriptional and transcriptional regulatory mechanisms were defined: IRE1β selectively degrades MTP mRNA in intestine to limit chylomicron production, and FoxO1 directly activates MTP transcription in liver, with insulin suppressing MTP via FoxO1 inhibition.","evidence":"Ire1b−/− mice and enterocyte studies; FoxO1 transgenic mice, hepatic FoxO1 RNAi, promoter binding assays","pmids":["18460335","18497885"],"confidence":"High","gaps":["Whether IRE1β acts via RIDD or another decay mechanism not fully resolved","FoxO1 binding site in MTP promoter fine-mapping not complete"]},{"year":2010,"claim":"A CLOCK–SHP circadian axis was shown to impose diurnal oscillation on MTP expression and plasma triglycerides, revealing a molecular basis for the circadian variation in VLDL production.","evidence":"Clock mutant and Shp−/− mouse models, serum shock oscillation assays, siRNA, MTP promoter analysis","pmids":["20674862"],"confidence":"High","gaps":["Relative contribution of intestinal vs. hepatic circadian MTP regulation not dissected","Whether other clock output genes synergize with SHP on MTP unknown"]},{"year":2012,"claim":"The IRE1α–XBP1s–PDI axis was shown to regulate hepatic MTP activity by controlling PDI abundance, linking ER stress signaling to VLDL lipidation capacity independently of apoB synthesis.","evidence":"Hepatocyte-specific Ire1α knockout mice, VLDL lipid composition, MTP activity and PDI expression measurement","pmids":["23040069"],"confidence":"High","gaps":["Whether XBP1s regulates PDI transcriptionally or post-transcriptionally not fully defined","Interaction between IRE1α and IRE1β pathways in dual-expressing tissues not explored"]},{"year":2013,"claim":"miR-30c was identified as a post-transcriptional repressor of MTP through direct 3ʹ UTR targeting; hepatic miR-30c overexpression reduced hyperlipidemia and atherosclerosis in vivo, establishing miR-30c as a physiological brake on MTP-dependent lipoprotein production.","evidence":"3ʹ UTR reporter assay, hepatic miR-30c overexpression and anti-miR in Apoe−/− mice, MTP activity and atherosclerosis quantification","pmids":["23749231"],"confidence":"High","gaps":["Endogenous signals that regulate miR-30c expression in liver not identified","Off-target effects of miR-30c on lipid synthesis pathway confound interpretation of MTP-specific contribution"]},{"year":2020,"claim":"PRAP1 was identified as a novel ER-localized lipid-binding partner that forms a ternary complex with TG and MTTP to facilitate lipid transfer; disruption of this complex in vivo reduced lipid absorption and protected against diet-induced obesity.","evidence":"Co-localization, direct TG-binding assay, MTTP lipid transfer assay, E85V mutagenesis, PRAP1-KO and E85V knock-in mice","pmids":["33168624"],"confidence":"High","gaps":["Stoichiometry and structural basis of the MTTP–PRAP1–TG ternary complex unknown","Whether PRAP1 modulates CD1d lipidation by MTP not tested"]},{"year":2022,"claim":"An exosomal route for MTTP was discovered in which adipocyte-derived exosomal MTTP complexes with PRAP1 in colorectal cancer cells to suppress ferroptosis via GPX4/xCT upregulation, implicating MTP in chemoresistance independent of canonical lipoprotein assembly.","evidence":"Exosome isolation, Co-IP of MTTP/PRAP1, GPX4/xCT/ZEB1 expression, lipid ROS measurement, CRC organoids and obese mouse tumor model with MTP inhibitor","pmids":["35978266"],"confidence":"Medium","gaps":["Mechanism by which MTTP/PRAP1 regulates ZEB1/GPX4 transcription not defined","Independent replication by another group needed","Whether exosomal MTTP retains lipid transfer activity not tested"]},{"year":null,"claim":"A high-resolution structure of the MTTP–PDI heterodimer with bound lipid substrate is lacking, and the precise mechanism by which MTTP transfers lipid to the growing apoB polypeptide in the ER lumen remains unresolved at the molecular level.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of MTTP–PDI complex","Mechanism of coupling between apoB translocation and MTP-mediated lipid loading not defined","Relative contribution of neutral lipid vs. phospholipid transfer to initial apoB lipidation unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[5,6,7,13,22]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[6,7,13,21]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[6,7,22]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,6,7,14,15,20,21]},{"term_id":"R-HSA-8963743","term_label":"Digestion and absorption","supporting_discovery_ids":[14,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,15,16]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,10,15,18]}],"complexes":["MTP heterodimer (MTTP large subunit + PDI/P4HB)","MTTP–PRAP1–TG ternary complex"],"partners":["P4HB","PRAP1","APOB","CD1D","HNF4A","HNF1A","FOXO1","NR0B2"],"other_free_text":[]},"mechanistic_narrative":"MTTP encodes the large (~88 kDa) subunit of microsomal triglyceride transfer protein, an ER-luminal heterodimer with protein disulfide isomerase (PDI) that transfers triglyceride, cholesteryl ester, and phospholipid to nascent apolipoprotein B during lipoprotein assembly, thereby controlling the number of apoB-containing particles secreted by hepatocytes and enterocytes [PMID:9106493, PMID:8876250, PMID:9211060]. Loss-of-function mutations in MTTP cause abetalipoproteinemia, confirmed by absent MTP activity in patient tissues and by identification of homozygous truncating and missense mutations across multiple cohorts [PMID:1439810, PMID:8361539, PMID:8533758]. MTP transcription is positively regulated by HNF-4α/HNF-1α and FoxO1 and repressed by the bile acid–FXR–SHP axis, the CLOCK–SHP circadian circuit, insulin signaling through MAPKerk, and post-transcriptionally by miR-30c-mediated mRNA degradation and intestine-specific IRE1β-dependent mRNA decay, while the IRE1α–XBP1s–PDI axis supports MTP activity in liver [PMID:7961826, PMID:18497885, PMID:15337761, PMID:20674862, PMID:23749231, PMID:18460335, PMID:23040069]. Beyond canonical lipoprotein assembly, an alternative-promoter-driven MTP isoform transfers phospholipid to CD1d in thymocytes and antigen-presenting cells, a function required for NKT cell development [PMID:17312007]."},"prefetch_data":{"uniprot":{"accession":"P55157","full_name":"Microsomal triglyceride transfer protein large subunit","aliases":[],"length_aa":894,"mass_kda":99.4,"function":"Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces (PubMed:15897609, PubMed:16478722, PubMed:22236406, PubMed:23475612, PubMed:25108285, PubMed:26224785, PubMed:8876250, PubMed:8939939). Required for the assembly and secretion of plasma lipoproteins that contain apolipoprotein B (PubMed:16478722, PubMed:23475612, PubMed:26224785, PubMed:8876250, PubMed:8939939). May be involved in regulating cholesteryl ester biosynthesis in cells that produce lipoproteins (By similarity)","subcellular_location":"Endoplasmic reticulum; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/P55157/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MTTP","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MTTP","total_profiled":1310},"omim":[{"mim_id":"610726","title":"TRUB PSEUDOURIDINE SYNTHASE FAMILY MEMBER 1; TRUB1","url":"https://www.omim.org/entry/610726"},{"mim_id":"590075","title":"TRANSFER RNA, MITOCHONDRIAL, PROLINE; MTTP","url":"https://www.omim.org/entry/590075"},{"mim_id":"545000","title":"MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF","url":"https://www.omim.org/entry/545000"},{"mim_id":"200100","title":"ABETALIPOPROTEINEMIA; ABL","url":"https://www.omim.org/entry/200100"},{"mim_id":"157147","title":"MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MTTP","url":"https://www.omim.org/entry/157147"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":259.2},{"tissue":"liver","ntpm":249.2}],"url":"https://www.proteinatlas.org/search/MTTP"},"hgnc":{"alias_symbol":["ABL"],"prev_symbol":["MTP"]},"alphafold":{"accession":"P55157","domains":[{"cath_id":"-","chopping":"302-365","consensus_level":"medium","plddt":92.017,"start":302,"end":365},{"cath_id":"2.20.50.20","chopping":"614-720","consensus_level":"medium","plddt":82.9306,"start":614,"end":720},{"cath_id":"1.20.58","chopping":"380-481","consensus_level":"medium","plddt":93.7876,"start":380,"end":481}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55157","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55157-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55157-F1-predicted_aligned_error_v6.png","plddt_mean":86.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MTTP","jax_strain_url":"https://www.jax.org/strain/search?query=MTTP"},"sequence":{"accession":"P55157","fasta_url":"https://rest.uniprot.org/uniprotkb/P55157.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55157/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55157"}},"corpus_meta":[{"pmid":"8616716","id":"PMC_8616716","title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","date":"1996","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8616716","citation_count":2866,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2179728","id":"PMC_2179728","title":"Acute leukaemia in bcr/abl transgenic mice.","date":"1990","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2179728","citation_count":610,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10391250","id":"PMC_10391250","title":"Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10391250","citation_count":496,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2204061","id":"PMC_2204061","title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2204061","citation_count":461,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14708008","id":"PMC_14708008","title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases.","date":"2004","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14708008","citation_count":392,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12654250","id":"PMC_12654250","title":"A myristoyl/phosphotyrosine switch regulates c-Abl.","date":"2003","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12654250","citation_count":378,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1525828","id":"PMC_1525828","title":"Dominant negative MYC blocks transformation by ABL oncogenes.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1525828","citation_count":376,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16721371","id":"PMC_16721371","title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16721371","citation_count":354,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23842646","id":"PMC_23842646","title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours.","date":"2013","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23842646","citation_count":351,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17710227","id":"PMC_17710227","title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17710227","citation_count":318,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9923858","id":"PMC_9923858","title":"In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.","date":"1999","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/9923858","citation_count":288,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3512096","id":"PMC_3512096","title":"Alternative 5' exons in c-abl mRNA.","date":"1986","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3512096","citation_count":281,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12124177","id":"PMC_12124177","title":"Critical role for Gab2 in transformation by BCR/ABL.","date":"2002","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12124177","citation_count":276,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11114745","id":"PMC_11114745","title":"Regulation of cell death by the Abl tyrosine kinase.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11114745","citation_count":230,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10979976","id":"PMC_10979976","title":"Bcr/Abl activates transcription of the Bcl-X gene through STAT5.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10979976","citation_count":217,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22156549","id":"PMC_22156549","title":"Molecular pathways: BCR-ABL.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22156549","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35978266","id":"PMC_35978266","title":"Adipocyte-Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35978266","citation_count":197,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11832214","id":"PMC_11832214","title":"Autoinhibition of c-Abl.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11832214","citation_count":195,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23040069","id":"PMC_23040069","title":"IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis.","date":"2012","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23040069","citation_count":188,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14676625","id":"PMC_14676625","title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL.","date":"2004","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14676625","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12783368","id":"PMC_12783368","title":"Molecular mechanisms of transformation by the BCR-ABL oncogene.","date":"2003","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/12783368","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11423669","id":"PMC_11423669","title":"STI571: targeting BCR-ABL as therapy for CML.","date":"2001","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/11423669","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24421390","id":"PMC_24421390","title":"The capable ABL: what is its biological function?","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24421390","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2440107","id":"PMC_2440107","title":"The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.","date":"1987","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2440107","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20674862","id":"PMC_20674862","title":"Diurnal regulation of MTP and plasma triglyceride by CLOCK is mediated by SHP.","date":"2010","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20674862","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10700189","id":"PMC_10700189","title":"Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10700189","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2852893","id":"PMC_2852893","title":"The viral and cellular forms of the Abelson (abl) oncogene.","date":"1988","source":"Advances in virus research","url":"https://pubmed.ncbi.nlm.nih.gov/2852893","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10713716","id":"PMC_10713716","title":"c-Abl: activation and nuclear targets.","date":"2000","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10713716","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12887890","id":"PMC_12887890","title":"Autoinhibition of Bcr-Abl through its SH3 domain.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12887890","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9376660","id":"PMC_9376660","title":"BCR-ABL gene variants.","date":"1997","source":"Bailliere's clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9376660","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10851051","id":"PMC_10851051","title":"JAK-STAT signaling activated by Abl oncogenes.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851051","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22000011","id":"PMC_22000011","title":"Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22000011","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18460335","id":"PMC_18460335","title":"IRE1beta inhibits chylomicron production by selectively degrading MTP mRNA.","date":"2008","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18460335","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26729027","id":"PMC_26729027","title":"Multifunctional Abl kinases in health and disease.","date":"2016","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/26729027","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23316053","id":"PMC_23316053","title":"Structure and dynamic regulation of Abl kinases.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23316053","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16754879","id":"PMC_16754879","title":"Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16754879","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23226582","id":"PMC_23226582","title":"The ins and outs of bcr-abl inhibition.","date":"2012","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23226582","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15268851","id":"PMC_15268851","title":"Requirement for Abl kinases in T cell receptor signaling.","date":"2004","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/15268851","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21236304","id":"PMC_21236304","title":"Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis.","date":"2011","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/21236304","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16497976","id":"PMC_16497976","title":"A common phosphotyrosine signature for the Bcr-Abl kinase.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16497976","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9365838","id":"PMC_9365838","title":"BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion.","date":"1997","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9365838","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2831714","id":"PMC_2831714","title":"Localization of gelsolin proximal to ABL on chromosome 9.","date":"1988","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2831714","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18413724","id":"PMC_18413724","title":"BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18413724","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11494128","id":"PMC_11494128","title":"Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11494128","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8791414","id":"PMC_8791414","title":"Nuclear tyrosine kinases: from Abl to WEE1.","date":"1996","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8791414","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1820686","id":"PMC_1820686","title":"Drosophila abl and genetic redundancy in signal transduction.","date":"1991","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/1820686","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9195915","id":"PMC_9195915","title":"Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9195915","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14704671","id":"PMC_14704671","title":"Controlling Abl: auto-inhibition and co-inhibition?","date":"2004","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14704671","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15148308","id":"PMC_15148308","title":"c-Abl phosphorylates Dok1 to promote filopodia during cell spreading.","date":"2004","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15148308","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20675402","id":"PMC_20675402","title":"Bag1 directly routes immature BCR-ABL for proteasomal degradation.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20675402","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11345193","id":"PMC_11345193","title":"Mechanisms of transformation by the BCR/ABL oncogene.","date":"2001","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11345193","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2687768","id":"PMC_2687768","title":"Nucleotide sequence analysis of human abl and bcr-abl cDNAs.","date":"1989","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/2687768","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16109371","id":"PMC_16109371","title":"Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16109371","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17312007","id":"PMC_17312007","title":"MTP regulated by an alternate promoter is essential for NKT cell development.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17312007","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19290927","id":"PMC_19290927","title":"Abl tyrosine kinases in T-cell signaling.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19290927","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12665579","id":"PMC_12665579","title":"Caspase-dependent cleavage of c-Abl contributes to apoptosis.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12665579","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19075013","id":"PMC_19075013","title":"c-Abl phosphorylates Hdmx and regulates its interaction with p53.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19075013","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15879768","id":"PMC_15879768","title":"Renal medullary carcinoma and ABL gene amplification.","date":"2005","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/15879768","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17227233","id":"PMC_17227233","title":"MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?","date":"2007","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/17227233","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8520030","id":"PMC_8520030","title":"Abl tyrosine protein kinase.","date":"1995","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8520030","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8336729","id":"PMC_8336729","title":"Oncogenic activation of c-ABL by mutation within its last exon.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8336729","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6302194","id":"PMC_6302194","title":"The human v-abl cellular homologue.","date":"1983","source":"Journal of molecular and applied genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6302194","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2232885","id":"PMC_2232885","title":"BCR-ABL and BCR proteins: biochemical characterization and localization.","date":"1990","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/2232885","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1451113","id":"PMC_1451113","title":"The bcr-abl gene in chronic myelogenous leukaemia.","date":"1992","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/1451113","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15910857","id":"PMC_15910857","title":"Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia.","date":"2005","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15910857","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21123451","id":"PMC_21123451","title":"BCR/ABL stimulates WRN to promote survival and genomic instability.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21123451","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35037731","id":"PMC_35037731","title":"Tunable Microgel-Templated Porogel (MTP) Bioink for 3D Bioprinting Applications.","date":"2022","source":"Advanced healthcare materials","url":"https://pubmed.ncbi.nlm.nih.gov/35037731","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8119916","id":"PMC_8119916","title":"p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8119916","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12086882","id":"PMC_12086882","title":"Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.","date":"2002","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12086882","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11779715","id":"PMC_11779715","title":"Abl: mechanisms of regulation and activation.","date":"2002","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/11779715","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29437150","id":"PMC_29437150","title":"PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia.","date":"2018","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29437150","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18759691","id":"PMC_18759691","title":"Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.","date":"2008","source":"Expert review of anticancer therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18759691","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25999467","id":"PMC_25999467","title":"Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding.","date":"2015","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25999467","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14684575","id":"PMC_14684575","title":"Ferroportin/IREG-1/MTP-1/SLC40A1 modulates the uptake of iron at the apical membrane of enterocytes.","date":"2004","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/14684575","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19229297","id":"PMC_19229297","title":"Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19229297","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15857311","id":"PMC_15857311","title":"Current biology of MTP: implications for selective inhibition.","date":"2005","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15857311","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10679949","id":"PMC_10679949","title":"Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia.","date":"2000","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10679949","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33168624","id":"PMC_33168624","title":"PRAP1 is a novel lipid-binding protein that promotes lipid absorption by facilitating MTTP-mediated lipid transport.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33168624","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25030663","id":"PMC_25030663","title":"Intestine-specific MTP and global ACAT2 deficiency lowers acute cholesterol absorption with chylomicrons and HDLs.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25030663","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19275932","id":"PMC_19275932","title":"Reciprocal regulation of Abl and receptor tyrosine kinases.","date":"2009","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/19275932","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22236406","id":"PMC_22236406","title":"Molecular and functional analysis of two new MTTP gene mutations in an atypical case of abetalipoproteinemia.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22236406","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3332859","id":"PMC_3332859","title":"The BCR/ABL hybrid gene.","date":"1987","source":"Bailliere's clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/3332859","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8251915","id":"PMC_8251915","title":"The role of myc in transformation by BCR-ABL.","date":"1993","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/8251915","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34504563","id":"PMC_34504563","title":"Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34504563","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15591787","id":"PMC_15591787","title":"Abi enhances Abl-mediated CDC2 phosphorylation and inactivation.","date":"2004","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/15591787","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36051879","id":"PMC_36051879","title":"Allosteric regulation of autoinhibition and activation of c-Abl.","date":"2022","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/36051879","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3465440","id":"PMC_3465440","title":"Functions of the abl oncogene.","date":"1986","source":"Cancer surveys","url":"https://pubmed.ncbi.nlm.nih.gov/3465440","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32098768","id":"PMC_32098768","title":"Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32098768","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39465372","id":"PMC_39465372","title":"Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39465372","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22357705","id":"PMC_22357705","title":"NR2F1 disrupts synergistic activation of the MTTP gene transcription by HNF-4α and HNF-1α.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22357705","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22391570","id":"PMC_22391570","title":"S6K1 determines the metabolic requirements for BCR-ABL survival.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22391570","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33744096","id":"PMC_33744096","title":"MTP deficiency caused by HADHB mutations: Pathophysiology and clinical manifestations.","date":"2021","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33744096","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24836440","id":"PMC_24836440","title":"BCR-ABL affects STAT5A and STAT5B differentially.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24836440","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9376659","id":"PMC_9376659","title":"The chimeric BCR-ABL gene.","date":"1997","source":"Bailliere's clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9376659","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27903968","id":"PMC_27903968","title":"Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27903968","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23318434","id":"PMC_23318434","title":"Dual regulation of Myc by Abl.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23318434","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31065499","id":"PMC_31065499","title":"Genome-wide identification and characterization of the metal tolerance protein (MTP) family in grape (Vitis vinifera L.).","date":"2019","source":"3 Biotech","url":"https://pubmed.ncbi.nlm.nih.gov/31065499","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9822717","id":"PMC_9822717","title":"Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9822717","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24721207","id":"PMC_24721207","title":"Mycobacterium tuberculosis pili (MTP), a putative biomarker for a tuberculosis diagnostic test.","date":"2014","source":"Tuberculosis (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/24721207","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32937901","id":"PMC_32937901","title":"Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32937901","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26912792","id":"PMC_26912792","title":"An improved smaller biotin ligase for BioID proximity labeling.","date":"2016","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/26912792","citation_count":665,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1439810","id":"PMC_1439810","title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1439810","citation_count":609,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8361539","id":"PMC_8361539","title":"Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8361539","citation_count":367,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9106493","id":"PMC_9106493","title":"Microsomal triglyceride transfer protein.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9106493","citation_count":268,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23749231","id":"PMC_23749231","title":"MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion.","date":"2013","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23749231","citation_count":254,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18497885","id":"PMC_18497885","title":"FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice.","date":"2008","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/18497885","citation_count":228,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8111381","id":"PMC_8111381","title":"Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein.","date":"1993","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8111381","citation_count":217,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15094225","id":"PMC_15094225","title":"Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.","date":"2004","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/15094225","citation_count":191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8876250","id":"PMC_8876250","title":"An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8876250","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15337761","id":"PMC_15337761","title":"Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15337761","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8533758","id":"PMC_8533758","title":"Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8533758","citation_count":125,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23382219","id":"PMC_23382219","title":"Structural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteins.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23382219","citation_count":121,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24842304","id":"PMC_24842304","title":"Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia.","date":"2014","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/24842304","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14615589","id":"PMC_14615589","title":"Haplotype-based identification of a microsomal transfer protein marker associated with the human lifespan.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14615589","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17784784","id":"PMC_17784784","title":"Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus.","date":"2007","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/17784784","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7961826","id":"PMC_7961826","title":"Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7961826","citation_count":107,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16518588","id":"PMC_16518588","title":"Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein.","date":"2006","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/16518588","citation_count":104,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30021884","id":"PMC_30021884","title":"Histone Interaction Landscapes Visualized by Crosslinking Mass Spectrometry in Intact Cell Nuclei.","date":"2018","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/30021884","citation_count":101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15654125","id":"PMC_15654125","title":"Retina expresses microsomal triglyceride transfer protein: implications for age-related maculopathy.","date":"2005","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15654125","citation_count":95,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17464986","id":"PMC_17464986","title":"Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?","date":"2007","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/17464986","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12716735","id":"PMC_12716735","title":"Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12716735","citation_count":91,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15504742","id":"PMC_15504742","title":"Human placenta secretes apolipoprotein B-100-containing lipoproteins.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15504742","citation_count":91,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15911777","id":"PMC_15911777","title":"No association between microsomal triglyceride transfer protein (MTP) haplotype and longevity in humans.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15911777","citation_count":83,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9211060","id":"PMC_9211060","title":"Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly.","date":"1997","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/9211060","citation_count":80,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42941,"output_tokens":2883,"usd":0.086034},"stage2":{"model":"claude-opus-4-6","input_tokens":6271,"output_tokens":2997,"usd":0.15942},"total_usd":0.58349,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":56273,"output_tokens":6430,"usd":0.132634},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9847,"output_tokens":3508,"usd":0.205402}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"IRE1α-XBP1s signaling regulates MTP (MTTP) activity by inducing PDI expression; hepatocyte-specific deletion of Ire1α reduces PDI expression, decreases MTP activity, and impairs VLDL assembly and triglyceride-rich lipoprotein secretion without affecting apoB synthesis or TG synthesis.\",\n      \"method\": \"Conditional hepatocyte-specific knockout of Ire1α, Western blot, lipid secretion assays, MTP activity assay\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with defined cellular phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"23040069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRE1β, but not its ubiquitous homolog IRE1α, selectively degrades MTP (MTTP) mRNA post-transcriptionally in enterocytes, thereby regulating chylomicron production; Ire1b-knockout mice fed high-fat/cholesterol diets secrete more chylomicrons and express more intestinal MTP protein.\",\n      \"method\": \"Ire1b knockout mice, primary enterocyte isolation, siRNA knockdown, MTP mRNA stability assays, chylomicron secretion assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined phenotype, replicated with siRNA knockdown and cell culture, orthogonal methods\",\n      \"pmids\": [\"18460335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CLOCK regulates diurnal MTP (MTTP) expression and plasma triglyceride levels through the small heterodimer partner (SHP/NR0B2); CLOCK transcriptionally upregulates SHP by binding to its E-box, and SHP suppresses MTP expression by binding to HNF4α/LRH-1 at the MTP promoter. Clock-mutant mice show sustained hypertriglyceridemia and high MTP expression, and Shp expression rescues this phenotype.\",\n      \"method\": \"Clock mutant mice, Shp knockout mice, CLOCK knockdown, promoter-luciferase reporter assays, ChIP, serum shock cyclic expression experiments\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models, promoter assays, ChIP, mechanistically defined pathway\",\n      \"pmids\": [\"20674862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MTP (MTTP) is required for NKT cell development; an MTP splice variant (MTPv1) expressed in thymocytes transfers phosphatidylethanolamine to CD1d in vitro. Pharmacological MTP inhibition in fetal thymic organ culture abrogates CD1d tetramer-positive NKT cell development and IL-4 production, without affecting CD1d surface expression.\",\n      \"method\": \"RT-PCR, Northern analysis, Edman degradation, in vitro lipid transfer assay, fetal thymic organ culture (FTOC) with MTP inhibitors, flow cytometry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro lipid transfer reconstitution plus FTOC functional assay with defined phenotypic readout\",\n      \"pmids\": [\"17312007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRAP1 is a lipid-binding protein that directly binds triglyceride and forms a ternary complex with MTTP and TG to facilitate MTTP-mediated lipid transfer and apoB-containing lipoprotein assembly. A single amino acid mutation (E85V) in PRAP1 disrupts ternary complex formation and impairs MTTP-mediated lipoprotein secretion. PRAP1-deficient and E85V knock-in mice show impaired lipid absorption and resistance to diet-induced obesity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro lipid transfer assay, site-directed mutagenesis, PRAP1-KO and knock-in mouse models, lipoprotein secretion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution with mutagenesis, confirmed in KO/knock-in mouse models\",\n      \"pmids\": [\"33168624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NR2F1 represses MTTP gene transcription by binding to a DR1 element in the MTTP promoter and recruiting nuclear receptor corepressor 1 (NCoR1), thereby disrupting synergistic activation of the promoter by HNF-4α and HNF-1α. NR2F1 does not affect individual HNF-4α or HNF-1 activities but abrogates their cooperative activation.\",\n      \"method\": \"Promoter-luciferase reporter assays, electrophoretic mobility shift assay (EMSA), co-immunoprecipitation, site-directed mutagenesis of promoter elements\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — promoter dissection with mutagenesis, EMSA, and reporter assays; multiple orthogonal methods\",\n      \"pmids\": [\"22357705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Intestinal MTP is required for cholesterol absorption via the chylomicron pathway; intestine-specific MTP ablation significantly increases intestinal triglyceride and cholesterol levels and reduces their transport in chylomicrons. Combined deficiency of intestinal MTP and global ACAT2 reduces cholesterol secretion with both chylomicrons and HDLs, demonstrating that free cholesterol accumulating in MTP/ACAT2 double-deficient intestines is unavailable for HDL secretion.\",\n      \"method\": \"Intestine-specific MTP knockout mice, global ACAT2 knockout mice, double-knockout mice, cholesterol absorption assays, lipoprotein fractionation\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean tissue-specific KO with defined pathway dissection and phenotypic readout\",\n      \"pmids\": [\"25030663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Loss-of-function mutations in the MTP (MTTP) gene cause abetalipoproteinemia (ABL); compound heterozygous missense mutations (D384A and G661A) in highly conserved regions of MTP cause hypobetalipoproteinemia. Functional analysis of mutations confirms that MTP activity is required for apoB-containing lipoprotein assembly and secretion.\",\n      \"method\": \"MTP gene sequencing, cell-based expression of mutant MTP proteins, biochemical characterization\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — human mutation identification with cell-based functional assay; single lab\",\n      \"pmids\": [\"15910857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A missense mutation p.Leu435His in MTTP abolishes MTP lipid transfer activity in COS-1 cells. An intronic deletion (c.619-5_619-2del) causes incomplete splicing defect with 26% residual normal splicing, explaining the atypical ABL phenotype with residual MTP activity.\",\n      \"method\": \"COS-1 cell expression of mutant MTP with activity assay, minigene splicing reporter assay in HeLa cells\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro MTP activity assay and splicing assay; single lab\",\n      \"pmids\": [\"22236406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MTTP, delivered via adipose-derived exosomes into colorectal cancer cells, inhibits ferroptosis by forming a complex with PRAP1 that suppresses ZEB1 expression and upregulates GPX4 and xCT, leading to decreased polyunsaturated fatty acid ratio and reduced lipid ROS levels, thereby promoting chemoresistance to oxaliplatin.\",\n      \"method\": \"Exosome isolation and transfer experiments, Co-IP (MTTP/PRAP1 complex), Western blot, lipid ROS assay, tumor organoids, obese mouse tumor implantation model, MTTP inhibition experiments\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP identifies complex, multiple functional readouts in vitro and in vivo, single lab\",\n      \"pmids\": [\"35978266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MTTP has an MTP splice variant (MTPv1) that, compared to canonical MTP, has equivalent protein disulfide isomerase (PDI) association, subcellular (ER) localization, triglyceride and phospholipid transfer activity, and ability to support apoB secretion, establishing that PDI association and ER localization are intrinsic properties of the MTP large subunit.\",\n      \"method\": \"Edman degradation of recombinant MTPv1, subcellular fractionation, lipid transfer assays, apoB secretion assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical reconstitution and in vitro lipid transfer assay; single lab\",\n      \"pmids\": [\"17312007\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MTTP (microsomal triglyceride transfer protein) is an endoplasmic reticulum-resident lipid transfer protein that, in complex with protein disulfide isomerase (PDI), transfers triglycerides and phospholipids to apolipoprotein B to enable VLDL and chylomicron assembly; its expression is transcriptionally regulated by HNF-4α/HNF-1α (activated) and NR2F1/SHP/CLOCK (repressed), post-transcriptionally regulated by IRE1β-mediated mRNA degradation in enterocytes, and its activity is facilitated by the lipid-binding co-factor PRAP1 which forms a ternary complex with MTTP and triglyceride; additionally, MTTP lipidates CD1d in thymocytes to support NKT cell development, and exosomal MTTP can enter colorectal cancer cells and suppress ferroptosis via a MTTP-PRAP1-GPX4/xCT axis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\nPapers about canonical MTTP (microsomal triglyceride transfer protein):\n- KEEP: [17], [19], [25], [33], [54], [59], [65], [76], [77], [78], [79], [81], [84], [90]\n- KEEP from curated: [4], [8], [9], [10], [11], [12], [15], [16], [17], [19], [20], [21], [22], [23], [25], [26], [27], [28], [29], [30]\n\nPapers about ABL/BCR-ABL (alias collision — MTTP is not ABL):\n- EXCLUDE: [1]-[16], [18], [20]-[24], [26]-[32], [34]-[58], [60]-[64], [66]-[73], [75], [80], [82]-[83], [85]-[89], [91], [93]-[96], [98], [100]\n\nPaper [67] = \"MTP bioink\" — symbol collision (microgel-templated porogel), EXCLUDE\nPaper [74] = Ferroportin/MTP-1/SLC40A1 — different protein (iron transporter), EXCLUDE\nPaper [92] = Mitochondrial Trifunctional Protein (HADHB gene) — different protein, EXCLUDE\nPaper [97] = plant Metal Tolerance Protein — symbol collision, EXCLUDE\nPaper [99] = Mycobacterium tuberculosis pili MTP — symbol collision, EXCLUDE\nPaper [39] = SNP association study, no mechanistic finding, EXCLUDE from extraction\nPaper [84] = expression/treatment study, EXCLUDE from mechanistic extraction\n\nCurated papers:\n- KEEP for mechanism: [4], [8], [9], [10], [11], [12], [15], [16], [17], [19], [20], [21], [22], [23], [25], [26], [27], [28], [29], [30]\n- EXCLUDE (genomics/longevity association): [1],[2],[3],[6],[7],[13],[14],[18],[24],[29 curated]\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"MTP activity and its 88-kDa large subunit are absent in intestinal biopsy samples from abetalipoproteinemia patients, establishing that a defect in MTP is the molecular basis of abetalipoproteinemia and that MTP is required for lipoprotein assembly.\",\n      \"method\": \"MTP activity assay and immunodetection in intestinal biopsies from ABL patients vs. controls\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical assay in patient tissue, foundational discovery replicated across multiple independent groups\",\n      \"pmids\": [\"1439810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"cDNA cloning of the large subunit of MTP revealed homozygous frameshift and nonsense mutations in two abetalipoproteinemic subjects, proving that defects in the MTP large-subunit gene are the proximal cause of ABL. The predicted amino acid sequence shows extensive homology to vitellogenin, which contains a large lipid-storage cavity.\",\n      \"method\": \"cDNA cloning, sequencing, and comparative genomic analysis; cell expression in COS-1 cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cloning plus patient mutation identification, replicated by independent groups same year\",\n      \"pmids\": [\"8361539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The human MTP gene was cloned and localized to chromosome 4q22-24. The C-terminal portion of MTP is necessary for triglyceride-transfer activity: deletion of 20 amino acids from the carboxyl terminus or a missense mutation of Cys878→Ser both abolished activity. Homozygous splice-disrupting mutations were identified in ABL patients.\",\n      \"method\": \"cDNA cloning, site-directed mutagenesis, expression in COS-1 cells with activity assay, patient mutation identification\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus in vitro activity assay defining required structural domain\",\n      \"pmids\": [\"8111381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"MTP gene promoter analysis showed cell-type-specific expression restricted to liver and intestinal cells, mediated by HNF-1 and HNF-4 binding elements in the -123 to -85 bp region. The promoter contains a modified sterol response element and a negative insulin response element; cholesterol positively and insulin negatively regulate MTP promoter activity.\",\n      \"method\": \"Promoter cloning, deletion analysis, transient transfection/luciferase reporter assay in liver, intestinal, and epithelial cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter dissection with multiple deletion constructs and cell-type comparisons\",\n      \"pmids\": [\"7961826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"All eight individuals in an ABL cohort carry mutations in the MTP gene on both alleles, each predicted to encode a truncated MTP protein, confirming MTP gene defects as the predominant cause of hereditary ABL and that an intact carboxyl terminus is required for triglyceride-transfer activity.\",\n      \"method\": \"MTP gene characterization, mutation screening across patient cohort, expression of engineered MTP forms in COS-1 cells\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis and expression assay across a patient cohort, confirming prior mechanistic findings\",\n      \"pmids\": [\"8533758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The MTP inhibitor BMS-200150 directly binds bovine MTP (Kd ~1.3 µM) and inhibits its triglyceride transfer activity (IC50 ~0.6 µM). Addition to HepG2 cells inhibits apoB secretion in a concentration-dependent manner, establishing that MTP-mediated neutral lipid transfer is mechanistically required for assembly of apoB-containing lipoproteins.\",\n      \"method\": \"In vitro MTP lipid transfer assay, binding assay, HepG2 cell apoB secretion assay with pharmacological inhibitor\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted transfer assay plus binding assay plus cellular functional assay\",\n      \"pmids\": [\"8876250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MTP is a heterodimer composed of the unique large (~88 kDa) subunit and protein disulfide isomerase (PDI); this complex catalyzes transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces and is located in the lumen of the ER in liver and intestine.\",\n      \"method\": \"Biochemical purification, activity assays, subunit characterization\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution and purification, widely replicated\",\n      \"pmids\": [\"9106493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MTP plays a key early role in lipoprotein assembly by transferring lipid to nascent apoB as it enters the ER lumen; MTP controls the number of apoB lipoprotein particles secreted but does not primarily determine the lipid composition of the particles.\",\n      \"method\": \"Heterologous expression systems and MTP inhibitor studies in hepatoma cell lines\",\n      \"journal\": \"Current opinion in lipidology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — convergent pharmacological and expression data from multiple systems, single review synthesis\",\n      \"pmids\": [\"9211060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Six novel MTP gene mutations (two nonsense, two missense, one frameshift, one splice-donor) were identified in Canadian ABL subjects, demonstrating wide genotypic heterogeneity and showing that clinical severity correlates with age at diagnosis and vitamin treatment onset rather than mutation type or position.\",\n      \"method\": \"MTP gene sequencing in patient cohort, genotype-phenotype correlation\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic characterization of multiple novel loss-of-function alleles confirming MTP's essential role\",\n      \"pmids\": [\"10679949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Insulin suppresses MTP gene transcription in HepG2 cells through the MAPKerk cascade (not PI3K), while MAPKp38 activity counterbalances this suppression, identifying the specific signal transduction pathways by which insulin regulates hepatic MTP expression and thereby VLDL production.\",\n      \"method\": \"Chemical inhibitors of signaling cascades, constitutively active and dominant-negative kinase constructs, MTP promoter-luciferase reporter assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genetic and pharmacological approaches dissecting the signaling pathway\",\n      \"pmids\": [\"12716735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The MTP gene promoter contains functional HNF-4α responsive elements, and HNF-4α regulates MTP expression directly and indirectly through HNF-1. Bile acid (CDCA) activates FXR, which induces small heterodimer partner (SHP), which suppresses HNF-4α activity, thereby reducing MTP mRNA, MTP protein, and apoB secretion.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), siRNA knockdown, dominant-negative HNF-4α overexpression, MTP promoter-luciferase reporter assays in HepG2 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus siRNA plus reporter assay, multiple orthogonal methods\",\n      \"pmids\": [\"15337761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MTP is expressed in retinal pigment epithelium (RPE) and retinal ganglion cells, and RPE cells (ARPE-19) synthesize and secrete neutral lipids (esterified cholesterol and triglyceride), implicating MTP-dependent lipoprotein assembly as a constitutive retinal function that may contribute to Bruch's membrane lipid deposition in age-related maculopathy.\",\n      \"method\": \"RT-PCR, immunodetection of MTP in retinal tissue and ARPE-19 cells; radiolabeled lipid secretion assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct detection of MTP expression plus functional lipid secretion assay in retinal cells\",\n      \"pmids\": [\"15654125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MTP has two additional functional roles beyond VLDL/chylomicron assembly: (1) production of small apoB-containing lipoprotein particles in cardiac myocytes, and (2) lipidation of CD1d (an MHC class I-related molecule) that presents glycolipid antigens to natural killer T (NKT) cells.\",\n      \"method\": \"Review synthesizing experimental data including lipid transfer assays and CD1d lipidation studies\",\n      \"journal\": \"Current topics in medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesis of experimental findings from multiple labs\",\n      \"pmids\": [\"15857311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MTP regulated by an alternative promoter is expressed as a novel splice variant (MTPv1) in non-apoB-secreting tissues including thymocytes and antigen-presenting cells. MTPv1 efficiently transfers phosphatidylethanolamine to CD1d in vitro. MTP inhibition in fetal thymic organ culture blocks NKT cell development and CD1d tetramer-positive cell generation, without affecting surface CD1d levels, establishing MTP's role in lipid loading of CD1d for NKT cell selection.\",\n      \"method\": \"PCR, Northern analysis, Edman degradation sequencing, in vitro phospholipid transfer to CD1d, fetal thymic organ culture with MTP antagonists, NKT cell quantification by tetramer staining\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution of CD1d lipidation plus genetic/pharmacological loss-of-function in thymic organ culture with defined cellular phenotype\",\n      \"pmids\": [\"17312007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRE1β (an ER stress sensor isoform expressed in intestine) selectively degrades MTP mRNA post-transcriptionally, thereby suppressing intestinal MTP expression and chylomicron production. Ire1b-/- mice develop hyperlipidemia due to increased intestinal MTP expression and chylomicron secretion; IRE1α does not regulate MTP mRNA.\",\n      \"method\": \"Ire1b-/- mouse phenotyping, primary enterocyte isolation, siRNA knockdown of IRE1β in cell culture, measurement of MTP mRNA stability and chylomicron secretion\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus siRNA knockdown plus primary cell studies with defined molecular mechanism\",\n      \"pmids\": [\"18460335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FoxO1 directly binds to and stimulates the MTP promoter, inducing MTP expression and VLDL production in a hepatic context. Constitutively active FoxO1 mice show enhanced MTP expression and hypertriglyceridemia; RNAi silencing of hepatic FoxO1 reduces MTP and VLDL production. Insulin suppresses MTP through inhibition of FoxO1.\",\n      \"method\": \"Promoter binding assays, FoxO1 transgenic mice, RNAi-mediated hepatic FoxO1 knockdown in adult mice, VLDL production and MTP activity measurements\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain- and loss-of-function with defined molecular and metabolic phenotypes\",\n      \"pmids\": [\"18497885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CLOCK regulates diurnal MTP expression and plasma triglyceride cycling through the small heterodimer partner (SHP/NR0B2). CLOCK binds the SHP E-box to upregulate SHP, which then suppresses MTP by binding HNF-4α/LRH-1 at the MTP promoter. Clock(mt/mt) mice show sustained hypertriglyceridemia and high MTP expression; Shp-/- mice lose diurnal variation in both MTP and triglycerides; SHP expression corrects hypertriglyceridemia in Clock(mt/mt) mice.\",\n      \"method\": \"Clock mutant and Shp-/- mouse models, serum shock oscillation assays, siRNA knockdown, MTP promoter analysis, plasma triglyceride and MTP expression measurements\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two genetic mouse models plus siRNA, defining a complete regulatory axis\",\n      \"pmids\": [\"20674862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The IRE1α–XBP1s arm of the unfolded protein response regulates VLDL assembly via MTP. Hepatocyte-specific Ire1α deletion reduces lipid partitioning into the ER lumen and impairs TG-rich VLDL assembly without affecting TG synthesis or apoB synthesis/secretion. The defect is due to reduced MTP activity caused by decreased PDI expression; thus the IRE1α–XBP1s–PDI axis controls MTP activity.\",\n      \"method\": \"Hepatocyte-specific Ire1α knockout mice, VLDL lipid composition analysis, MTP activity assay, PDI expression measurement\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic knockout with mechanistic dissection identifying PDI as intermediate\",\n      \"pmids\": [\"23040069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NR2F1 represses synergistic activation of the MTP promoter by HNF-4α/HNF-1α by binding to a DR1 element and recruiting nuclear receptor corepressor 1 (NCoR1), without affecting individual activities of HNF-4α or HNF-1α alone. This defines a mechanism for MTP repression in undifferentiated intestinal cells.\",\n      \"method\": \"MTP promoter-luciferase reporter assays, electrophoretic mobility shift assay (EMSA), co-transfection of HNF-4α, HNF-1α, NR2F1, and NCoR1\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter assays with defined transcription factor combinations\",\n      \"pmids\": [\"22357705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Two novel MTTP mutations in an atypical ABL patient (missense p.Leu435His and intronic deletion c.619-5_619-2del) were characterized: the missense mutant showed negligible MTP activity in COS-1 cells; the intronic deletion caused incomplete splicing defect retaining 26% normal splicing, explaining the milder atypical phenotype through residual MTP activity.\",\n      \"method\": \"MTP activity assay in COS-1 cells (missense mutant expression), minigene splicing reporter assay in HeLa cells (intronic deletion)\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — functional activity assay plus splicing assay linking genotype to residual MTP function and atypical phenotype\",\n      \"pmids\": [\"22236406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MicroRNA-30c (miR-30c) interacts with the 3' UTR of MTP mRNA and induces its degradation, reducing MTP activity and apoB secretion. miR-30c also independently reduces lipid synthesis. Hepatic overexpression of miR-30c in mice reduced hyperlipidemia and atherosclerosis; anti-miR-30c increased hyperlipidemia and atherosclerosis.\",\n      \"method\": \"3' UTR reporter assay, hepatic miR-30c overexpression and anti-miR knockdown in mice, MTP activity assay, VLDL/apoB secretion measurements, atherosclerosis quantification in Apoe-/- mice\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain- and loss-of-function with direct MTP activity measurement and 3' UTR validation\",\n      \"pmids\": [\"23749231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Intestinal-specific MTP deletion increases intestinal triglyceride and cholesterol levels and reduces their transport with chylomicrons. Combined intestinal MTP and global ACAT2 deficiency reduces cholesterol secretion with both chylomicrons and HDLs, demonstrating that MTP is required for chylomicron assembly and that free cholesterol accumulated during ACAT2 deficiency is unavailable for HDL secretion when MTP is absent. ACAT2 deficiency increases hepatic MTP activity to compensate for hepatosteatosis.\",\n      \"method\": \"Intestine-specific MTP knockout mice, global ACAT2 knockout mice, double knockout mice; cholesterol absorption assay, lipoprotein fractionation, MTP activity assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mouse models with precise metabolic phenotyping\",\n      \"pmids\": [\"25030663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRAP1 is a novel lipid-binding protein that colocalizes with MTTP in the ER and directly binds triglyceride. PRAP1 facilitates MTTP-mediated lipid transfer by forming a ternary complex with TG and MTTP; mutation E85V disrupts ternary complex formation and abolishes PRAP1's ability to facilitate MTTP-mediated apoB-containing lipoprotein assembly and secretion. PRAP1-deficient and E85V knock-in mice show reduced lipid absorption and resistance to diet-induced obesity and hepatosteatosis.\",\n      \"method\": \"Co-localization studies, direct TG-binding assay, MTTP-mediated lipid transfer assay, E85V mutagenesis, apoB lipoprotein secretion assay, PRAP1-KO and E85V knock-in mouse models on chow and HFD\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro binding and transfer assay plus mutagenesis plus in vivo mouse models, multiple orthogonal methods\",\n      \"pmids\": [\"33168624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Adipocyte-derived exosomal MTTP is transferred to colorectal cancer (CRC) cells where it forms a complex with PRAP1; the MTTP/PRAP1 complex inhibits ZEB1 expression and upregulates GPX4 and xCT, decreasing polyunsaturated fatty acid ratio and lipid ROS levels, thereby suppressing ferroptosis and promoting chemoresistance to oxaliplatin. MTTP inhibition restored oxaliplatin sensitivity in CRC organoids and obese mouse tumor models.\",\n      \"method\": \"Exosome isolation and characterization, Co-IP of MTTP/PRAP1 complex, GPX4/xCT/ZEB1 expression analysis, lipid ROS measurement, CRC organoids, obese mouse tumor implantation model with MTP inhibitor treatment\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP defining complex plus multiple functional assays in organoids and in vivo models, single lab study\",\n      \"pmids\": [\"35978266\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MTTP encodes a heterodimeric ER-luminal lipid transfer protein (large ~88-kDa subunit complexed with PDI) that is essential for lipoprotein assembly by transferring triglyceride, cholesteryl ester, and phospholipid to nascent apoB as it enters the ER lumen (controlling particle number rather than lipid composition); its transcription is regulated by HNF-4α/HNF-1α (positively), FoxO1 (insulin-repressible), CLOCK–SHP axis (circadian), bile acid–FXR–SHP (repressive), and miR-30c (post-transcriptional degradation), while IRE1β degrades MTP mRNA intestine-specifically and the IRE1α–XBP1s–PDI axis supports MTP activity in the liver; beyond canonical lipoprotein assembly, MTP lipidates CD1d to enable NKT cell development, is expressed in retina and cardiac myocytes, and an exosomal form suppresses ferroptosis in cancer cells via a MTTP–PRAP1 complex that regulates GPX4 and xCT.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MTTP encodes the large subunit of microsomal triglyceride transfer protein, an endoplasmic reticulum-resident lipid transfer enzyme that, in obligate complex with protein disulfide isomerase (PDI), transfers triglycerides and phospholipids onto apolipoprotein B to drive VLDL and chylomicron assembly and secretion [PMID:23040069, PMID:25030663]. Transcriptional activation of MTTP depends on cooperative HNF-4α/HNF-1α signaling at its promoter, which is repressed by NR2F1 via NCoR1 recruitment and by the CLOCK–SHP circadian axis, while post-transcriptionally IRE1β selectively degrades MTTP mRNA in enterocytes to limit chylomicron output [PMID:22357705, PMID:20674862, PMID:18460335]. The lipid-binding cofactor PRAP1 forms a ternary complex with MTTP and triglyceride to facilitate lipid transfer, and MTTP additionally lipidates CD1d with phosphatidylethanolamine in thymocytes, a function required for NKT cell development [PMID:33168624, PMID:17312007]. Loss-of-function mutations in MTTP cause abetalipoproteinemia [PMID:15910857, PMID:22236406].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing that the MTP large subunit intrinsically associates with PDI, localizes to the ER, and transfers both triglycerides and phospholipids to support apoB secretion resolved whether these properties depend on isoform-specific sequences or are core features of MTTP.\",\n      \"evidence\": \"Edman degradation, subcellular fractionation, lipid transfer assays, and apoB secretion assays comparing canonical MTP and splice variant MTPv1\",\n      \"pmids\": [\"17312007\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab biochemical characterization; no crystal structure of the MTTP–PDI heterodimer to define binding interface\", \"Relative physiological contributions of splice variants in vivo unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of compound heterozygous loss-of-function mutations in MTTP as causative for abetalipoproteinemia established that MTP activity is essential for apoB-containing lipoprotein assembly in humans.\",\n      \"evidence\": \"MTTP gene sequencing in patients, cell-based expression and functional analysis of D384A and G661A mutants\",\n      \"pmids\": [\"15910857\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited to single kindred; genotype–phenotype spectrum across many mutations not fully mapped\", \"No structural explanation for why specific residues are critical\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that MTTP transfers phosphatidylethanolamine to CD1d and is required for NKT cell development revealed a non-canonical, immune-regulatory function for a lipid transfer protein previously studied only in lipoprotein metabolism.\",\n      \"evidence\": \"In vitro lipid transfer assay with CD1d substrate, fetal thymic organ culture with MTP pharmacological inhibitors, flow cytometry for NKT cells\",\n      \"pmids\": [\"17312007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pharmacological inhibitor approach cannot exclude off-target effects; genetic confirmation in thymocyte-specific MTTP KO not shown\", \"Identity of endogenous CD1d lipid cargo loaded by MTTP in vivo not determined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that IRE1β selectively degrades MTTP mRNA in enterocytes defined a tissue-specific post-transcriptional checkpoint controlling chylomicron production, explaining how intestinal lipid absorption is restrained.\",\n      \"evidence\": \"Ire1b knockout mice, primary enterocyte isolation, siRNA knockdown, MTP mRNA stability and chylomicron secretion assays\",\n      \"pmids\": [\"18460335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise IRE1β cleavage site(s) on MTTP mRNA not mapped\", \"Whether IRE1β regulation of MTTP is relevant under normal chow versus only high-fat conditions unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linking the circadian clock to MTTP transcription via the CLOCK→SHP→HNF4α/LRH-1 pathway explained diurnal oscillations in plasma triglyceride and showed that MTP expression is gated by a nuclear receptor–corepressor cascade.\",\n      \"evidence\": \"Clock mutant and Shp knockout mice, CLOCK knockdown, ChIP, promoter-luciferase reporters, serum shock circadian expression experiments\",\n      \"pmids\": [\"20674862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of circadian MTTP regulation versus other clock-controlled lipid genes to diurnal triglyceride rhythm not isolated\", \"Chromatin remodeling events at the MTTP promoter during clock cycling not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing that NR2F1 represses MTTP by recruiting NCoR1 to a DR1 element and specifically disrupting cooperative HNF-4α/HNF-1α activation clarified how basal MTTP transcription is kept in check by an orphan nuclear receptor.\",\n      \"evidence\": \"Promoter-luciferase reporters with site-directed mutagenesis, EMSA, co-immunoprecipitation in cell lines\",\n      \"pmids\": [\"22357705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance assessed only by overexpression; no NR2F1 tissue-specific KO tested\", \"Whether NR2F1 regulation differs between hepatocytes and enterocytes not examined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that IRE1α–XBP1s signaling sustains MTTP activity by inducing PDI expression revealed that ER stress sensing feeds forward into lipoprotein assembly, explaining reduced VLDL secretion in hepatic IRE1α deficiency.\",\n      \"evidence\": \"Conditional hepatocyte-specific Ire1α knockout, Western blot for PDI, MTP activity assay, lipid secretion assays\",\n      \"pmids\": [\"23040069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether XBP1s directly binds the PDI promoter or acts indirectly not resolved\", \"Contribution of other UPR branches (PERK, ATF6) to MTTP–PDI complex stability not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"A missense mutation (p.Leu435His) abolishing MTP activity and an intronic deletion permitting 26% residual splicing explained atypical abetalipoproteinemia phenotypes, refining genotype–phenotype understanding.\",\n      \"evidence\": \"COS-1 cell expression of mutant MTTP with lipid transfer activity assay, minigene splicing reporter assay in HeLa cells\",\n      \"pmids\": [\"22236406\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study; limited patient numbers\", \"No structural model explaining why Leu435His eliminates transfer activity\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Intestine-specific MTTP ablation proved that MTP is required for both triglyceride and cholesterol transport via the chylomicron pathway, and combined MTTP/ACAT2 deficiency showed that free cholesterol accumulating in enterocytes cannot be redirected to HDL secretion.\",\n      \"evidence\": \"Intestine-specific MTP knockout, global ACAT2 knockout, double-knockout mice, cholesterol absorption and lipoprotein fractionation assays\",\n      \"pmids\": [\"25030663\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether compensatory basolateral cholesterol efflux pathways are upregulated not fully characterized\", \"Long-term consequences of intestinal lipid accumulation on enterocyte viability not assessed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of PRAP1 as a triglyceride-binding cofactor that forms a ternary complex with MTTP and TG to facilitate lipid transfer provided the first evidence of an accessory factor required for efficient MTTP-mediated lipoprotein assembly.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro lipid transfer assay, site-directed mutagenesis (E85V), PRAP1-KO and knock-in mouse models\",\n      \"pmids\": [\"33168624\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the ternary complex not resolved\", \"Whether PRAP1 participates in MTTP-mediated CD1d lipidation unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Exosomal delivery of MTTP into colorectal cancer cells where it complexes with PRAP1 to suppress ferroptosis via GPX4/xCT upregulation suggested a non-canonical extracellular role for MTTP in tumor chemoresistance.\",\n      \"evidence\": \"Exosome isolation and transfer, Co-IP of MTTP–PRAP1, lipid ROS assay, tumor organoids, obese mouse tumor model\",\n      \"pmids\": [\"35978266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding; MTTP–ZEB1 regulatory mechanism not mechanistically defined\", \"Whether exosomal MTTP retains lipid transfer activity or acts through a distinct mechanism unclear\", \"Relevance beyond the obesity–CRC context not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of the MTTP–PDI–PRAP1 ternary complex bound to lipid substrate is lacking, leaving the mechanism of lipid hand-off to apoB unresolved at the atomic level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cryo-EM or crystal structure of MTTP–PDI heterodimer or ternary complex with PRAP1\", \"Mechanism by which MTTP discriminates between apoB lipidation and CD1d lipidation not defined\", \"In vivo quantitative contribution of each transcriptional and post-transcriptional regulatory arm to steady-state MTTP levels not integrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 3, 4, 10]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [3, 4, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 4, 6]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [\n      \"MTTP–PDI heterodimer\",\n      \"MTTP–PDI–PRAP1 ternary complex\"\n    ],\n    \"partners\": [\n      \"P4HB\",\n      \"PRAP1\",\n      \"CD1D\",\n      \"HNF4A\",\n      \"NR2F1\",\n      \"SHP\",\n      \"ERN2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MTTP encodes the large (~88 kDa) subunit of microsomal triglyceride transfer protein, an ER-luminal heterodimer with protein disulfide isomerase (PDI) that transfers triglyceride, cholesteryl ester, and phospholipid to nascent apolipoprotein B during lipoprotein assembly, thereby controlling the number of apoB-containing particles secreted by hepatocytes and enterocytes [PMID:9106493, PMID:8876250, PMID:9211060]. Loss-of-function mutations in MTTP cause abetalipoproteinemia, confirmed by absent MTP activity in patient tissues and by identification of homozygous truncating and missense mutations across multiple cohorts [PMID:1439810, PMID:8361539, PMID:8533758]. MTP transcription is positively regulated by HNF-4α/HNF-1α and FoxO1 and repressed by the bile acid–FXR–SHP axis, the CLOCK–SHP circadian circuit, insulin signaling through MAPKerk, and post-transcriptionally by miR-30c-mediated mRNA degradation and intestine-specific IRE1β-dependent mRNA decay, while the IRE1α–XBP1s–PDI axis supports MTP activity in liver [PMID:7961826, PMID:18497885, PMID:15337761, PMID:20674862, PMID:23749231, PMID:18460335, PMID:23040069]. Beyond canonical lipoprotein assembly, an alternative-promoter-driven MTP isoform transfers phospholipid to CD1d in thymocytes and antigen-presenting cells, a function required for NKT cell development [PMID:17312007].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Identification that MTP activity and its large subunit are absent in abetalipoproteinemia patients established MTP as essential for lipoprotein assembly and pinpointed the molecular defect underlying ABL.\",\n      \"evidence\": \"MTP activity assay and immunodetection in intestinal biopsies from ABL patients versus controls\",\n      \"pmids\": [\"1439810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise molecular identity and sequence of the large subunit not yet known\", \"Mechanism of lipid transfer not resolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Cloning of the MTP large subunit cDNA and identification of loss-of-function mutations in ABL patients proved the gene is causative for ABL and revealed structural homology to vitellogenin, suggesting a lipid-binding cavity architecture; mutagenesis demonstrated the C-terminal domain is required for triglyceride transfer activity.\",\n      \"evidence\": \"cDNA cloning, patient mutation identification, site-directed mutagenesis, COS-1 cell expression and activity assay\",\n      \"pmids\": [\"8361539\", \"8111381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure to define lipid-binding cavity directly\", \"Heterodimer formation requirements not yet mapped\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Dissection of the MTP promoter revealed cell-type-specific regulation by HNF-1 and HNF-4, a sterol response element, and a negative insulin response element, explaining tissue-restricted expression in liver and intestine.\",\n      \"evidence\": \"Promoter deletion analysis, luciferase reporter assays in liver, intestinal, and non-expressing cell lines\",\n      \"pmids\": [\"7961826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of each promoter element not tested\", \"Post-transcriptional regulation not yet explored\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Pharmacological inhibition of MTP with a specific small molecule (BMS-200150) demonstrated that neutral lipid transfer activity is mechanistically required for apoB-containing lipoprotein secretion, rather than just correlated with it.\",\n      \"evidence\": \"In vitro lipid transfer assay, direct binding measurement, apoB secretion assay in HepG2 cells with MTP inhibitor\",\n      \"pmids\": [\"8876250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of inhibitor binding unknown\", \"In vivo pharmacokinetics not established\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Biochemical characterization established MTP as an ER-luminal heterodimer of the unique 88 kDa subunit with PDI that transfers TG, CE, and PL, and showed MTP controls particle number rather than lipid composition.\",\n      \"evidence\": \"Biochemical purification and reconstituted lipid transfer assays; pharmacological and expression studies in hepatoma cells\",\n      \"pmids\": [\"9106493\", \"9211060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which PDI contributes to transfer activity not defined\", \"Structural basis of lipid substrate selectivity unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The HNF-4α→HNF-1α transcriptional axis was shown to directly activate MTP, while the bile acid–FXR–SHP pathway suppresses MTP by inhibiting HNF-4α at the promoter, connecting bile acid signaling to VLDL output.\",\n      \"evidence\": \"ChIP, siRNA knockdown, dominant-negative constructs, MTP promoter-luciferase in HepG2 cells\",\n      \"pmids\": [\"15337761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation in FXR or SHP knockout liver not yet performed in this study\", \"Contribution of SHP-independent FXR effects not ruled out\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery of an alternative-promoter-driven MTP isoform in thymocytes and APCs that transfers phospholipid to CD1d established a non-canonical function of MTP in NKT cell development, independent of apoB-lipoprotein assembly.\",\n      \"evidence\": \"Identification of MTPv1 splice variant, in vitro phospholipid transfer to CD1d, fetal thymic organ culture with MTP antagonists and NKT cell quantification\",\n      \"pmids\": [\"17312007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lipid species loaded onto CD1d by MTP in vivo not fully characterized\", \"Whether MTPv1 also transfers neutral lipids in immune cells not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Two opposing post-transcriptional and transcriptional regulatory mechanisms were defined: IRE1β selectively degrades MTP mRNA in intestine to limit chylomicron production, and FoxO1 directly activates MTP transcription in liver, with insulin suppressing MTP via FoxO1 inhibition.\",\n      \"evidence\": \"Ire1b−/− mice and enterocyte studies; FoxO1 transgenic mice, hepatic FoxO1 RNAi, promoter binding assays\",\n      \"pmids\": [\"18460335\", \"18497885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IRE1β acts via RIDD or another decay mechanism not fully resolved\", \"FoxO1 binding site in MTP promoter fine-mapping not complete\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"A CLOCK–SHP circadian axis was shown to impose diurnal oscillation on MTP expression and plasma triglycerides, revealing a molecular basis for the circadian variation in VLDL production.\",\n      \"evidence\": \"Clock mutant and Shp−/− mouse models, serum shock oscillation assays, siRNA, MTP promoter analysis\",\n      \"pmids\": [\"20674862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of intestinal vs. hepatic circadian MTP regulation not dissected\", \"Whether other clock output genes synergize with SHP on MTP unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The IRE1α–XBP1s–PDI axis was shown to regulate hepatic MTP activity by controlling PDI abundance, linking ER stress signaling to VLDL lipidation capacity independently of apoB synthesis.\",\n      \"evidence\": \"Hepatocyte-specific Ire1α knockout mice, VLDL lipid composition, MTP activity and PDI expression measurement\",\n      \"pmids\": [\"23040069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether XBP1s regulates PDI transcriptionally or post-transcriptionally not fully defined\", \"Interaction between IRE1α and IRE1β pathways in dual-expressing tissues not explored\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"miR-30c was identified as a post-transcriptional repressor of MTP through direct 3ʹ UTR targeting; hepatic miR-30c overexpression reduced hyperlipidemia and atherosclerosis in vivo, establishing miR-30c as a physiological brake on MTP-dependent lipoprotein production.\",\n      \"evidence\": \"3ʹ UTR reporter assay, hepatic miR-30c overexpression and anti-miR in Apoe−/− mice, MTP activity and atherosclerosis quantification\",\n      \"pmids\": [\"23749231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous signals that regulate miR-30c expression in liver not identified\", \"Off-target effects of miR-30c on lipid synthesis pathway confound interpretation of MTP-specific contribution\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"PRAP1 was identified as a novel ER-localized lipid-binding partner that forms a ternary complex with TG and MTTP to facilitate lipid transfer; disruption of this complex in vivo reduced lipid absorption and protected against diet-induced obesity.\",\n      \"evidence\": \"Co-localization, direct TG-binding assay, MTTP lipid transfer assay, E85V mutagenesis, PRAP1-KO and E85V knock-in mice\",\n      \"pmids\": [\"33168624\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of the MTTP–PRAP1–TG ternary complex unknown\", \"Whether PRAP1 modulates CD1d lipidation by MTP not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"An exosomal route for MTTP was discovered in which adipocyte-derived exosomal MTTP complexes with PRAP1 in colorectal cancer cells to suppress ferroptosis via GPX4/xCT upregulation, implicating MTP in chemoresistance independent of canonical lipoprotein assembly.\",\n      \"evidence\": \"Exosome isolation, Co-IP of MTTP/PRAP1, GPX4/xCT/ZEB1 expression, lipid ROS measurement, CRC organoids and obese mouse tumor model with MTP inhibitor\",\n      \"pmids\": [\"35978266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which MTTP/PRAP1 regulates ZEB1/GPX4 transcription not defined\", \"Independent replication by another group needed\", \"Whether exosomal MTTP retains lipid transfer activity not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of the MTTP–PDI heterodimer with bound lipid substrate is lacking, and the precise mechanism by which MTTP transfers lipid to the growing apoB polypeptide in the ER lumen remains unresolved at the molecular level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of MTTP–PDI complex\", \"Mechanism of coupling between apoB translocation and MTP-mediated lipid loading not defined\", \"Relative contribution of neutral lipid vs. phospholipid transfer to initial apoB lipidation unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [5, 6, 7, 13, 22]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [6, 7, 13, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [6, 7, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 6, 7, 14, 15, 20, 21]},\n      {\"term_id\": \"R-HSA-8963743\", \"supporting_discovery_ids\": [14, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 15, 16]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 10, 15, 18]}\n    ],\n    \"complexes\": [\n      \"MTP heterodimer (MTTP large subunit + PDI/P4HB)\",\n      \"MTTP–PRAP1–TG ternary complex\"\n    ],\n    \"partners\": [\n      \"P4HB\",\n      \"PRAP1\",\n      \"APOB\",\n      \"CD1D\",\n      \"HNF4A\",\n      \"HNF1A\",\n      \"FOXO1\",\n      \"NR0B2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}